HIVandHepatitis.com
DDW 2009    |    EASL 2009    |    ISVHLD 2009    |    AASLD 2008
 Google Custom Search
Hepatitis C Top News Articles
FDA Advisory Panel Urges "Black Box" Warning -- and Potential Ban -- on Prescription Acetaminophen Combinations Due to Liver Toxicity
7-03-2009
Albumin Interferon (Albuferon) and HCV Polymerase Inhibitor PSI-7851 Advance in Clinical Trials
7-03-2009
CDC Researchers Release Latest Hepatitis A, B, and C Statistics
6-23-2009
Detectable HCV RNA at Week 8 Is Best Predictor of Relapse in Genotype 1 Hepatitis C Patients Treated with Pegylated Interferon plus Ribavirin
6-23-2009
Effectiveness of Pegylated Interferon plus Ribavirin for Chronic Hepatitis C Patients with HCV Genotypes 5 or 6
6-19-2009
Blood Pressure Drug Losartan Associated with Liver Fibrosis Regression in Small Study
6-19-2009
FDA Alert Warns of Elevated Risk of Death in Liver Transplant Recipients Who Switch to Rapamune (Sirolimus)
6-16-2009
Many People with Chronic Hepatitis B and C Do Not Receive Appropriate Treatment
6-16-2009
Older Genotype 3 Chronic Hepatitis C Patients Do Not Respond as Well to Interferon-based Therapy
6-16-2009
Metabolic Syndrome Is Associated with Increased Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients
6-9-2009
Strategies for Managing Acetaminophen-related Liver Disease and Acute Liver Failure
6-5-2009
Vitamin B12 Levels May Help Predict Response to Interferon-based Therapy for Chronic Hepatitis C
6-5-2009
HCV Viral Load Decline at Day 2 of Interferon-based Therapy Predicts Sustained Response, Explains Poorer Outcomes in African-Americans
6-2-2009
Virco and Siemens Diagnostics Sign Licensing Agreement Allowing Virco to Develop New Platform for Use in Development of New Therapies for Hepatitis C
6-2-2009
Report Predicts Costly Epidemic of Advanced Liver Disease among Baby Boomers with Chronic Hepatitis C
5-29-2009
Reduced Dose and Duration of PegIntron plus Ribavirin Is Not as Effective as Standard Therapy for Genotype 2 and 3 Hepatitis C Patients
5-29-2009
IDEAL Study Shows that Greater Hemoglobin Decline during Treatment with Pegylated Interferon plus Ribavirin Is Associated with Better Response
5/22/09
On World Hepatitis Day, Ask "Am I Number 12?"
5/22/09
On World Hepatitis Day, Ask "Am I Number 12?"
5/19/09
Active Injection Drug Users and Those on Opiate Substitution Treatment Can Have Good Hepatitis C Therapy Outcomes
5/19/09
Researchers Report Promising Results from Studies of 3 Therapeutic HCV Vaccines
5/19/09
FDA Approves Dose Adjustments of PegIntron and Rebetol for Certain Patients with Chronic Hepatitis C
5/15/09
Hepatitis C Treatment Is More Successful before Progression to Advanced Liver Damage
5/15/09
Chronic Hepatitis C Patients with Metabolic Syndrome Are at Greater Risk of Death
5/08/09
Extended 72-week Treatment with Pegylated Interferon plus Ribavirin Did Not Improve Outcomes among Slow Responder Hepatitis C Patients
5/08/09
Early Treatment of Acute Hepatitis C with Pegylated Interferon Monotherapy Produces Better Results than Delayed Combination Therapy
5/05/09
Pegylated Interferon alfa-2b (PegIntron) Maintenance Monotherapy May Reduce Esophageal Varices in Hepatitis C Patients with Cirrhosis
5/05/09
Adding Telaprevir Improves Sustained Response to Pegylated Interferon plus Ribavirin in Genotype 1 Chronic Hepatitis C Patients (PROVE3)
5/01/09
Experimental HCV Protease Inhibitor SCH 900518, with or without Pegylated Interferon, Appears Safe and Exhibits Good Antiviral Activity
5/01/09
FDA Will Require Additional Warning Labels for Over-the-Counter Painkillers, Including Tylenol, Aspirin and Ibuprofen
5/01/09
Promising Early Results from the First Clinical Trial of a Combination Regimen of 2 Oral Antiviral Agents for Chronic Hepatitis C
4/28/09
Adding Boceprevir to PegIntron/Ribavirin Significantly Improves Sustained Virological Response in Chronic Hepatitis C Patients
4/28/09
Genes that Regulate Interferon Signaling May Help Explain Reduced Response to Hepatitis C Therapy in African-American Patients
4/28/09
Re-treatment of Chronic Hepatitis C Patients Who Do Not Respond to Pegylated Interferon Alfa-2b (PegIntron)
4/24/09
Liver Cancer Drug Sorafenib (Nexavar) May Also Alleviate Complications Due to Cirrhosis
4/24/09
Interferon-based Therapy for Hepatitis C Improves Fibrosis Even in Individuals without Virological Response
4/21/09
Sustained Response to Interferon-based Therapy Reduces Risk of Diabetes in Hepatitis C Patients
4/21/09
HCV Vaccine Development
4/13/09
A Small Proportion of Hepatitis C Patients Develop Liver Cancer despite Sustained Response to Interferon-based Therapy
4/13/09
Treatment for HCV/HBV Coinfection
4/10/09
Pharmasset Initiates First Clinical Trial of Second-generation HCV Polymerase Inhibitor PSI-7851
4/10/09
Pegylated Interferon alfa-2a (Pegasys) Relapse Rates in Genotype 1 Chronic Hepatitis C Patients Depend on Weight-based Ribavirin Dosage
4/07/09
Overview of the Current Standard of Care for Treatment of Chronic Hepatitis C
4/03/09
HCV Reinfection and Superinfection Are Common among Injection Drug Users
3/24/09
Review Finds Albumin Interferon for Chronic Hepatitis C Is Effective and Well-tolerated; Phase 3 Results Show Non-inferiority to Pegylated Interferon
3/20/2009
Long-term Maintenance Interferon Did Not Prevent Hepatocellular Carcinoma among Chronic Hepatitis C Patients in HALT-C Study
3/17/2009
FDA Approves New Indication for PegIntron plus Ribavirin for Certain Patients Who Failed Prior Hepatitis C Treatment
3/13/2009
U.S. Liver Cancer Rate Triples, but Survival Improves
3/13/2009
Vertex Acquires VCH-222 and VCH-759, Two Experimental Oral HCV Polymerase Inhibitors
3/09/2009
Merck Will Buy Schering-Plough for $41.1 Billion
3/09/2009
Open Phase 3 Study of Eltrombopag for Raising Platelet Levels in Patients with Chronic Liver Disease and Thrombocytopenia
2/27/09
Phase 1 OPTIMA Trial Finds Controlled-release Nitazoxanide Improves Response to Pegylated Interferon plus Ribavirin
2/27/09
Abbott and Enanta Announce First Clinical Trial of Oral HCV Protease Inhibitor ABT-450
2/20/2009
iTherX Pharmaceuticals Announces Phase 2a Proof-of-concept Trial of First Hepatitis C Virus Entry Inhibitor
2/13/2009
Cyclical Treatment Interruption in Patients Taking Interferon-based Therapy for Chronic Hepatitis C
2/10/2009
Hepatitis C Virus May Persists at Low Levels after Sustained Response to Treatment; Liver Cancer May Develop Years Later
2/06/2009
Extended Pegylated Interferon plus Ribavirin Therapy Improves Sustained Response Rate in Slow Responder Genotype 1b Hepatitis C Patients
2/03/2009
Debiopharm Begins Randomization of Participants in Phase 2b Trial of Cyclophilin Inhibitor Debio 025 for Chronic Hepatitis C
2/03/2009
Adherence to Pegylated Interferon/ribavirin Therapy for Hepatitis C and Early Treatment Response
1/30/2009
Schering-Plough Completes Enrollment of Phase 3 Trial of HCV Protease Inhibitor Boceprevir
1/30/2009
Combination of Virus and Host Factors Predict Virological Response to Pegylated Interferon plus Ribavirin for Chronic Hepatitis C
1/27/2009
Elevated Risk of Biliary and Pancreas Cancer in Chronic Hepatitis C Patients
1/27/2009
Companies Announce Phase 1b Study Data for Experimental HCV Polymerase Inhibitor ANA598 and Cyclophilin Inhibitor SCY635
1/23/2009
Liver Biopsies Indicate Persistent Inflammation and Fibrosis in HCV Antibody Positive People with Undetectable HCV RNA
1/23/2009
Early Discontinuation of Ribavirin May Be Appropriate for Selected Genotype 2 or 3 Chronic Hepatitis C Patients
1/20/2009
New Hepatitis C Treatment Trials: HCV Polymerase Inhibitor R7128, Nucleotide Prodrug IDX184, and Albumin Interferon (Albuferon)
1/20/2009
Vital Therapies Starts Phase 2 Trial of Artificial Liver Support System
1/20/2009
Latino Hepatitis C Patients Have a Lower Rate of Sustained Response to Pegylated interferon plus Ribavirin than Whites
1/16/2009
InterMune Reports Results from Triple Combination Study of HCV Protease Inhibitor ITMN-191
1/16/2009
Adefovir plus Hepatitis C Therapy May Prevent HBV Reactivation in HBV-HCV Coinfected Patients
1/16/2009
MELD Eliminated Racial Disparities in Liver Transplantation, but Women Are Still at a Disadvantage
1/16/2009
Effects of Alcohol on HCV Replication and Treatment Response
1/13/2009
Study Shows Treating Prisoners with Hepatitis C Is Cost Effective
1/13/2009
Albumin Interferon (Albuferon) Works as Well as Pegylated Interferon in ACHIEVE 2/3 Trial - 1/13/2009
Naturally Occurring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-naive Hepatitis C Patients - 1/09/2009
PegIntron plus Ribavirin Approved for Children with Chronic Hepatitis C - 1/05/2009
New Genetic Test May Help Predict Response to Hepatitis C Treatment - 1/05/2009
Liver Disease Progression and Treatment Response in Latino and Asian Patients with Chronic Hepatitis C - 12/12/2008
Silibinin Milk Thistle Extract Demonstrates Antiviral Activity in Non-responders to Interferon-based Therapy for Chronic Hepatitis C - 12/12/2008
SAMe Improves Early Response to Pegylated Interferon/ribavirin in Small Study - 12/12/2008
Is Maintenance Therapy with Pegylated Interferon Monotherapy Ineffective-or Even Harmful to Patients? - 12/12/2008
Long-term Low-dose Pegylated Interferon May Improve Liver Inflammation and Fibrosis in a Select Subgroup of Prior Non-responders - 12/08/2008
Results of the IDEAL Study of Treatment of African Americans with Chronic Hepatitis C: A Slide Set Review - 12/082008
CD4 T-cell Responses to HCV during and after Interferon-based Therapy for Chronic Hepatitis C - 12/05/2008
Nitazoxanide Enhances Anti-HCV Activity of Pegylated interferon/ribavirin and STAT-C Agents - 12/02/2008
Prodrug Taribavirin Produces Equivalent Response, but Less Anemia than Ribavirin at 48 Weeks - 12/02/2008
Extended Duration Pegylated Interferon/ribavirin for Prior Non-responders and Relapsers - 11/25/2008
Three New STAT-C Agents Show Promise in Preclinical Studies and Early Clinical Trials: MK-7009, ANA598, and IDX375 - 11/25/2008
Therapies to Manage Insulin Resistance Improve Response to Interferon-based Therapy in Chronic Hepatitis C Patients - 11/21/2008
Canadian POWeR Study Finds Patients with Advanced Liver Disease Respond Poorly to Pegylated Interferon plus Ribavirin - 11/21/2008
Genotype 1 HCV Patients with Early but Not Rapid Response May Benefit from 72 Weeks of Pegylated Interferon plus Ribavirin - 11/18/2008
Sexual Desire, Function, and Satisfaction in Men Undergoing Treatment with Interferon-based Therapy for Chronic Hepatitis C - 11/14/2008
HCV Polymerase Inhibitor R7128 Demonstrates Good Antiviral Activity in Genotype 2 or 3 Prior Non-responders and Relapsers - 11/14/2008
HCV Protease Inhibitor ITMN-191 (R7227) Demonstrates Antiviral Potency in Genotype 1 Patients; New ITMN-5489 Also Under Study - 11/14/2008
R7128 plus ITMN-191 Perform Well in Laboratory Study; STAT-C Combination Clinical Trial Now Underway - 11/14/2008
HCV Protease Inhibitor Telaprevir (VX-950) Continues to Perform Well in PROVE Trials - 11/11/2008
Experimental HCV Protease Inhibitor TMC435350 Demonstrates Favorable Safety and Efficacy in Phase 2a Trial - 11/11/2008
Investigational HCV Protease Inhibitor BI 201335 Exhibits Promising Antiviral Activity - 11/11/2008
HCV Polymerase Inhibitor PF-00868554 Inhibits Viral Replication in Treatment-naive Patients - 11/11/2008
IDEAL Researchers Look at Predictors of Response to Pegylated Interferon plus Ribavirin, including Race/ethnicity and Anemia - 11/07/2008
Several “STAT-C” Agents Discussed at the Liver Meeting - 11/07/2008
HCV Protease Inhibitor Boceprevir plus Pegylated Interferon/Ribavirin Increases Sustained Virological Response Rate: SPRINT-1 Study - 11/04/2008
Many U.S. Veterans -- both HIV Negative and HIV Positive -- Do Not Receive Treatment for Chronic Hepatitis C - 11/04/2008
Hepatitis C Virus Infection Is Associated with Elevated Cardiovascular Risk despite Lower Blood Lipid Levels - 10/28/2008
(13)C-methacetin Breath Test for Non-invasive Assessment of Liver Fibrosis in Chronic Hepatitis C Patients - 10/24/2008
Tibotec Begins Enrolling Phase III Study of HCV Protease Inhibitor Telaprevir for Hepatitis C Patients with Prior Treatment Failure - 10/24/2008
Response to Pegylated Interferon plus Ribavirin in Asian Patients with Genotype 1 Chronic Hepatitis C - 10/21/2008
Genelabs Announces Data on 3 New HCV Polymerase Inhibitors - 10/21/2008
Hepatitis C Virus Coinfection May Suppress Hepatitis B Virus Replicatio - 10/17/08
Pegylated Interferon plus Ribavirin Produces High Sustained Response Rate in HBV-HCV Coinfected Individuals - 10/17/08
Sustained Virological Response Indicates Long-term HCV Eradication in People Successfully Treated for Chronic Hepatitis C - 10/14/08
24 Weeks of Pegylated Interferon plus Ribavirin May Be Sufficient for Selected Genotype 1/4 Chronic Hepatitis C Patients with Rapid Response - 10/14/08
Individuals with HCV Genotype 6 Respond Well to Pegylated Interferon plus Ribavirin - 10/14/08
Higher Doses of Pegylated Interferon and Ribavirin May Increase Sustained Response Rates in Hard-to-Treat Patients with Chronic Hepatitis C - 10/10/08
Sustained Virological Response to Pegylated Interferon plus Ribavirin for Chronic Hepatitis C Does Not Always Prevent Hepatocellular Carcinoma - 10/10/08
Hepatitis C Treatment in Prisons Is Feasible and Produces Good Outcome - 10/07/08
SciClone Experimental Immunomodulator SCV-07 Shows Promise as Monotherapy in Prior Relapsers to Standard Treatment for Chronic Hepatitis C - 10/03/08
Natural Prevalence of Resistance to HCV Protease Inhibitors - 9/25/08
Albumin Interferon (Albuferon) Administered Once Every 2-4 Weeks May Be As Effective as Once-weekly Pegylated Interferon - 9/23/08
Kidney Disease in Patients with Chronic Hepatitis C - 9/23/08
Further Evidence Shows that Hepatitis C Virus (HCV) Can Be Transmitted through Snorting Drugs - 9/19/08
HCV May Be Transmitted via Blood-contaminated Surfaces - 9/19/08
Is HCV Transmitted within Families in Endemic Countries? - 9/19/08
Liver Fibrosis Progression Rates in HCV Monoinfected and HIV-HCV Coinfected Individuals - 9/16/08
Impact of Diet on Fibrosis Progression and Response to Treatment in People with Chronic Hepatitis C - 9/16/08
Successful Treatment Is Reducing Mortality Due to Hepatitis C in France - 9/12/2008
Combination Therapy with Investigational HCV Polymerase Inhibitor R7128 Produces Rapid Response in Patients with Genotype 2/3 HCV - 9/12/2008
STORM Trial to Assess Sorafenib (Nexavar) as Adjuvant Therapy for Patients with Liver Cancer - 9/12/2008
Genetic Variation Linked to Sustained Response to Pegylated Interferon plus Ribavirin in HALT-C Trial - 9/09/2008
Older Donor Liver Grafts May Be Suitable for Chronic Hepatitis C Patients Requiring Transplantation - 9/05/08
Insulin-sensitizing Agent Pioglitazone (Actos) Did Not Improve Response to Re-treatment with Pegylated Interferon plus Ribavirin - 8/29/2008
Rosiglitazone (Avandia) Improves Liver Enzyme Levels and Steatosis -- but not Fibrosis -- in Patients with Non-alcoholic Fatty Liver Disease - 8/29/2008
Are HIV Positive People More Likely to Relapse after Completion of Hepatitis C Treatment with Pegylated Interferon plus Ribavirin - 8/19/2008
Body Weight Affects Relapse Rates in Latinos with Genotype 2/3 Hepatitis C Treated with Pegylated Interferon Alfa-2a (Pegasys) plus Ribavirin - 8/12/2008
Pharmasset Releases Preliminary Data from Phase 1 Study of Investigational HCV Polymerase Inhibitor R7128 - 8/08/2008
Rapid Viral Response and Sustained Treatment Outcome: A Comparison between 2 HCV RNA Assays - 8/05/2008
Eight Weeks of Pegylated Interferon plus Ribavirin for Genotype 2 Chronic HCV Patients with Rapid Virological Response (RVR) - 8/05/2008
74 Percent of Genotype 1 HCV Patients in Experimental HCV PI Boceprevir Phase II Study Achieve Sustained Virologic Response (SVR) at 48 Weeks - 8/05/2008
Detectable HCV Is Associated with Altered Serum Triglyceride and Cholesterol Level - 8/01/08
Genetic Variations May Help Explain Racial/ethnic Differences in Immune Response to Hepatitis C Virus - 7/29/08
Study Demonstrates Safety of Erythropoiesis-stimulating Agents for Managing Ribavirin-related Anemia in Hepatitis C Patients - 7/29/08
Hepatocellular Carcinoma Rates Vary Widely Across Sex and Racial/Ethnic Groups - 7/25/08
Two Studies Look at Promising Therapies for Liver Cancer - 7/25/08
Telaprevir plus Pegylated Interferon and Ribavirin Produces Rapid Response and Is Well Tolerated in 28-day Study - 7/22/08
Active Injection Drug Use Does Not Impair Sustained Response to Hepatitis C Treatment in Adherent Patients - 7/22/08
Comparison of the Pegylated Interferons Pegasys and PegIntron for Treatment of Chronic Hepatitis C: Analysis of 16 Randomized Trials - 7/18/08
Obesity and Steatosis Influence Serum and Liver Inflammatory Markers in People with Chronic Hepatitis C - 7/18/08
Obesity and Diabetes Are Linked to Increased Risk of Liver Cancer - 7/18/08
Experimental HCV Polymerase Inhibitor R1626 Demonstrates Potent Viral Suppression, but Often Causes Neutropenia - 7/15/08
12- Versus 24-week Treatment with Pegylated Interferon plus Ribavirin for Genotype 2 or 3 Chronic Hepatitis C Patients - 7/11/08
Prevalence of Hepatitis C Virus Infection among Injection Drug Users in the U.S. - 7/11/08
FDA Revises Process for Responding to Drug Approval Applications from Pharmaceutical Companies - 7/11/08
Studies Explore Lower Doses of Pegylated Interferon and Ribavirin for People with Hepatitis C Virus Genotypes 2 or 3 - 7/08/08
Adequate Ribavirin Exposure after the First Dose Predicts Sustained Virological Response to Hepatitis C Treatment in Genotype 1 Patients - 7/08/08
HCV Genotype 1 Patients with High Viral Load Do Better with 48 vs 24 Weeks of Treatment, despite Rapid Virological Response - 7/04/08
European Commission Approves Shorter 16-week Course of Pegasys plus Ribavirin for Rapid Responders with HCV Genotypes 2 or 3 and Low Viral Load - 7/04/08
Insulin Resistance and Diabetes Increase the Risk of Liver Fibrosis and Hepatocellular Carcinoma in People with Chronic Hepatitis C - 7/04/08
Sustained Response to Interferon-based Therapy Reduces the Likelihood of Type 2 Diabetes - 6/24/08
Aspirin (Acetylsalicylic Acid) Inhibits HCV Replication in Laboratory Study - 6/20/08
Course of Chronic Hepatitis C in Children - 6/17/08
Study Review Confirms High Cure Rate for Acute Hepatitis C, but Treatment Dilemma Persists - 6/17/08
Vertex Reports Encouraging Data from PROVE3 Trial of HCV Protease Inhibitor Telaprevir (VX-950) - 6/13/08
Pegylated Interferon plus Ribavirin for 48 Weeks is Superior to 24 Weeks for Patients with HCV Genotype 6 - 6/13/08
Association between Hepatitis B and C Virus Infection and Extrahepatic Bile Duct Cancer - 6/13/08
Selected Hepatitis C Patients with Decompensated Cirrhosis Can Benefit from Interferon-based Therapy prior to Liver Transplantation - 6/10/08
Herbal Product Stevioside Inhibits HCV Replication and Curcumin Suppresses Fibrogenic Cell Activity in Laboratory Studies - 6/10/08
Active and Recovering Injection Drug Users Can Benefit from Hepatitis C Treatment if They Maintain Good Adherence - 6/10/08
InterMune and Anadys Begin Phase 1 Clinical Trials of Experimental HCV Therapies ITMN-191 and ANA598 - 6/06/08
Mortality Due to Hepatitis C in the U.S.: Has the Worst Passed? - 6/06/08
Marijuana Use Sparks Liver Transplant Controversy - 6/06/08
Chronic Hepatitis C May Contribute to an Elevated Risk of Bone Fractures in Postmenopausal Women - 6/03/08
Sustained Virological Response to Pegylated Interferon Alfa-2b (PegIntron) with or without Ribavirin Predicts Continued Response through 5 Years - 5/30/08
Very Early Response to Interferon-based Therapy for Hepatitis C Is Apparent within the First 24 Hours - 5/30/08
Schering Plough Initiates Phase 3 Studies with Experimental Oral HCV Protease Inhibitor Boceprevir in Treatment-naive HCV Patients and in Those Who Failed Prior Treatment - 5/23/08
Significance of Transient HCV Viral Load "Blips" during Interferon-based Therapy for Chronic Hepatitis C - 5/23/08
Safety and Activity of Once-Monthly Albinterferon Alfa-2b (Albuferon) in Genotype 2/3 Chronic Hepatitis C Patients - 5/23/08
Antiviral Activity, Pharmacodynamics, and Quality of Life in Genotype 1 Hepatitis C Patients Treated with Albinterferon (Albuferon) - 5/23/08
Response to Controlled-release Interferon Alfa-2b (Locteron) in Genotype 1 Hepatitis C Patients - 5/23/08
Symptoms and Response to Interferon plus Ribavirin in Children with Chronic Hepatitis C - 5/23/08
Response to Interferon-based Therapy in Hispanic Patients with Chronic Hepatitis C - 5/20/08
Platelet Count Is a Strong Predictor of Sustained Response to Pegylated Interferon/ribavirin in Prior Non-Responders (EPIC 3) - 5/20/08
Amino Acid Substitutions in HCV Core Region Predict Poor Response to Pegylated Interferon/ribavirin in Genotype 1b Patients - 5/20/08
HCV May Inhibit HBV Replication in HCV-HBV Coinfected Patients - 5/20/08
FibroScan Liver Stiffness Measurement Distinguishes Fast and Slow Fibrosis Patterns after Liver Transplantation - 5/16/08
Incidence of and Risk Factors for Hepatocellular Carcinoma in Hepatitis C Patients with Advanced Liver Disease: HALT-C Trial - 5/16/08